Skip to main content

Table 1 Evaluation of TRAIL receptors cell surface expression in MPM cell lines. Expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 was evaluated by flow cytometry. The values represent the fluorescence intensity of the receptors normalized for the negative control. Data are expressed as mean ± s.d. from three independent experiments. *n.e.-not expressed

From: Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

 

TRAIL-receptors

MPM cell lines

TRAIL-R1

TRAIL-R2

TRAIL-R3

TRAIL-R4

TRAIL-resistant

    

H2052

14.0 ± 0.4

58.0 ± 3.1

2.6 ± 0.1

1.7 ± 0.4

SPC212

30.5 ± 0.2

64.0 ± 2.4

1.2 ± 0.1

4.2 ± 0.8

ZL34

10.9 ± 0.5

65.5 ± 4.2

1.5 ± 0.2

2.0 ± 0.5

H226

12.7 ± 0.8

66.6 ± 6.5

n.e*

n.e

TRAIL-partially resistant

    

SDM6

15.8 ± 0.3

33.6 ± 3.2

1.3 ± 0.1

n.e

SDM13

10.3 ± 0.2

15.3 ± 0.4

1.2 ± 0.3

1.4 ± 0.2

TRAIL-sensitive

    

H2452

1.5 ± 0.1

34.0 ± 2.0

2.5 ± 0.2

1.7 ± 0.3

SCP111

33.0 ± 1.0

33.6 ± 1.5

2.1 ± 0.2

1.5 ± 0.2

ZL5

13.2 ± 0.2

55.7 ± 3.2

1.1 ± 0.1

1.3 ± 0.2

ZL55

32.8 ± 2.0

38.2 ± 3.5

n.e

1.2 ± 0.4

H28

26.4 ± 0.4

22.0 ± 0.8

1.3 ± 0.2

2.5 ± 0.5

SDM4

24.5 ± 0.3

58.0 ± 4.2

1.4 ± 0.2

1.5 ± 0.1

MSTO-211H

2.3 ± 0.1

60.4 ± 3.2

1.3 ± 0.3

1.3 ± 0.2